News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Glycotex Inc. Obtains Active IND From US FDA for GLYC-101 Wound Healing Compound


1/8/2008 9:55:49 AM

ROCKVILLE, MD--(Marketwire - January 07, 2008) - Glycotex, Inc. announced today that it had obtained an active Investigational New Drug Application (IND) from the US Food and Drug Administration (FDA) for the start of a phase IIa clinical trial of its lead product candidate GLYC-101, administered topically for the treatment of burn wounds.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES